nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.057	0.215	CbGbCtD
Sirolimus—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0385	0.145	CbGbCtD
Sirolimus—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0367	0.139	CbGbCtD
Sirolimus—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0327	0.124	CbGbCtD
Sirolimus—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.032	0.121	CbGbCtD
Sirolimus—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0303	0.114	CbGbCtD
Sirolimus—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0192	0.0726	CbGbCtD
Sirolimus—MTOR—leg—chronic obstructive pulmonary disease	0.019	0.169	CbGeAlD
Sirolimus—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0181	0.0685	CbGbCtD
Sirolimus—EIF4E—respiratory system—chronic obstructive pulmonary disease	0.0122	0.109	CbGeAlD
Sirolimus—EIF4E—connective tissue—chronic obstructive pulmonary disease	0.0108	0.0955	CbGeAlD
Sirolimus—EIF4E—lung—chronic obstructive pulmonary disease	0.00649	0.0576	CbGeAlD
Sirolimus—FGF2—bronchus—chronic obstructive pulmonary disease	0.00613	0.0545	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—chronic obstructive pulmonary disease	0.006	0.0533	CbGeAlD
Sirolimus—FGF2—trachea—chronic obstructive pulmonary disease	0.00551	0.0489	CbGeAlD
Sirolimus—MTOR—respiratory system—chronic obstructive pulmonary disease	0.00473	0.042	CbGeAlD
Sirolimus—FKBP1A—respiratory system—chronic obstructive pulmonary disease	0.00425	0.0378	CbGeAlD
Sirolimus—MTOR—connective tissue—chronic obstructive pulmonary disease	0.00416	0.037	CbGeAlD
Sirolimus—FGF2—lung—chronic obstructive pulmonary disease	0.00396	0.0351	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—chronic obstructive pulmonary disease	0.00381	0.0338	CbGeAlD
Sirolimus—FKBP1A—connective tissue—chronic obstructive pulmonary disease	0.00374	0.0332	CbGeAlD
Sirolimus—FKBP1A—bronchus—chronic obstructive pulmonary disease	0.0035	0.0311	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—chronic obstructive pulmonary disease	0.00342	0.0304	CbGeAlD
Sirolimus—FKBP1A—trachea—chronic obstructive pulmonary disease	0.00314	0.0279	CbGeAlD
Sirolimus—MTOR—lung—chronic obstructive pulmonary disease	0.00251	0.0223	CbGeAlD
Sirolimus—FKBP1A—lung—chronic obstructive pulmonary disease	0.00226	0.02	CbGeAlD
Sirolimus—SLC47A1—lung—chronic obstructive pulmonary disease	0.00194	0.0172	CbGeAlD
Sirolimus—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.00185	0.0164	CbGeAlD
Sirolimus—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000984	0.00873	CbGeAlD
Sirolimus—CYP3A5—lung—chronic obstructive pulmonary disease	0.000983	0.00873	CbGeAlD
Sirolimus—ABCB1—trachea—chronic obstructive pulmonary disease	0.000727	0.00645	CbGeAlD
Sirolimus—ABCB1—lung—chronic obstructive pulmonary disease	0.000522	0.00464	CbGeAlD
Sirolimus—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000383	0.000917	CcSEcCtD
Sirolimus—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000382	0.000914	CcSEcCtD
Sirolimus—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000381	0.000912	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000381	0.000911	CcSEcCtD
Sirolimus—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00038	0.000909	CcSEcCtD
Sirolimus—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000379	0.000906	CcSEcCtD
Sirolimus—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000378	0.000904	CcSEcCtD
Sirolimus—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.000897	CcSEcCtD
Sirolimus—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000375	0.000897	CcSEcCtD
Sirolimus—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.000897	CcSEcCtD
Sirolimus—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000375	0.000897	CcSEcCtD
Sirolimus—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000375	0.000896	CcSEcCtD
Sirolimus—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000374	0.000895	CcSEcCtD
Sirolimus—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000373	0.000891	CcSEcCtD
Sirolimus—Infection—Formoterol—chronic obstructive pulmonary disease	0.000373	0.000891	CcSEcCtD
Sirolimus—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000369	0.000884	CcSEcCtD
Sirolimus—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000369	0.000884	CcSEcCtD
Sirolimus—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000369	0.000884	CcSEcCtD
Sirolimus—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000368	0.000881	CcSEcCtD
Sirolimus—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000368	0.000881	CcSEcCtD
Sirolimus—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000368	0.00088	CcSEcCtD
Sirolimus—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000368	0.00088	CcSEcCtD
Sirolimus—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000367	0.000879	CcSEcCtD
Sirolimus—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000367	0.000879	CcSEcCtD
Sirolimus—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000367	0.000879	CcSEcCtD
Sirolimus—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000366	0.000876	CcSEcCtD
Sirolimus—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000366	0.000876	CcSEcCtD
Sirolimus—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000365	0.000873	CcSEcCtD
Sirolimus—Infection—Montelukast—chronic obstructive pulmonary disease	0.000365	0.000873	CcSEcCtD
Sirolimus—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000364	0.000872	CcSEcCtD
Sirolimus—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000364	0.000872	CcSEcCtD
Sirolimus—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000363	0.000869	CcSEcCtD
Sirolimus—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00036	0.000862	CcSEcCtD
Sirolimus—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00036	0.000861	CcSEcCtD
Sirolimus—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.00036	0.00086	CcSEcCtD
Sirolimus—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000359	0.000859	CcSEcCtD
Sirolimus—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000357	0.000854	CcSEcCtD
Sirolimus—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.000847	CcSEcCtD
Sirolimus—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.000847	CcSEcCtD
Sirolimus—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000352	0.000842	CcSEcCtD
Sirolimus—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00035	0.000838	CcSEcCtD
Sirolimus—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00035	0.000838	CcSEcCtD
Sirolimus—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.00035	0.000838	CcSEcCtD
Sirolimus—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000349	0.000834	CcSEcCtD
Sirolimus—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.000834	CcSEcCtD
Sirolimus—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000347	0.000831	CcSEcCtD
Sirolimus—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000347	0.00083	CcSEcCtD
Sirolimus—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000346	0.000827	CcSEcCtD
Sirolimus—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000345	0.000826	CcSEcCtD
Sirolimus—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000344	0.000823	CcSEcCtD
Sirolimus—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000342	0.000819	CcSEcCtD
Sirolimus—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000342	0.000819	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000342	0.000818	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000342	0.000818	CcSEcCtD
Sirolimus—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000339	0.000812	CcSEcCtD
Sirolimus—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.000812	CcSEcCtD
Sirolimus—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.000808	CcSEcCtD
Sirolimus—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000337	0.000807	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000335	0.000801	CcSEcCtD
Sirolimus—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000334	0.0008	CcSEcCtD
Sirolimus—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.0008	CcSEcCtD
Sirolimus—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000333	0.000798	CcSEcCtD
Sirolimus—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000333	0.000798	CcSEcCtD
Sirolimus—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000332	0.000795	CcSEcCtD
Sirolimus—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000331	0.000792	CcSEcCtD
Sirolimus—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000331	0.000792	CcSEcCtD
Sirolimus—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00033	0.00079	CcSEcCtD
Sirolimus—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00033	0.00079	CcSEcCtD
Sirolimus—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00033	0.000789	CcSEcCtD
Sirolimus—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000329	0.000787	CcSEcCtD
Sirolimus—Injury—Prednisone—chronic obstructive pulmonary disease	0.000327	0.000782	CcSEcCtD
Sirolimus—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000327	0.000781	CcSEcCtD
Sirolimus—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000326	0.00078	CcSEcCtD
Sirolimus—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000325	0.000778	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000324	0.000775	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000324	0.000775	CcSEcCtD
Sirolimus—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000323	0.000774	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.000772	CcSEcCtD
Sirolimus—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000321	0.000767	CcSEcCtD
Sirolimus—Pain—Formoterol—chronic obstructive pulmonary disease	0.000321	0.000767	CcSEcCtD
Sirolimus—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000321	0.000767	CcSEcCtD
Sirolimus—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000321	0.000767	CcSEcCtD
Sirolimus—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.000766	CcSEcCtD
Sirolimus—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.00032	0.000765	CcSEcCtD
Sirolimus—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000318	0.000761	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000317	0.000759	CcSEcCtD
Sirolimus—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.000755	CcSEcCtD
Sirolimus—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.000753	CcSEcCtD
Sirolimus—Pain—Montelukast—chronic obstructive pulmonary disease	0.000314	0.000752	CcSEcCtD
Sirolimus—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000313	0.00075	CcSEcCtD
Sirolimus—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000312	0.000747	CcSEcCtD
Sirolimus—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000312	0.000746	CcSEcCtD
Sirolimus—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000311	0.000743	CcSEcCtD
Sirolimus—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00031	0.000743	CcSEcCtD
Sirolimus—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.00031	0.000741	CcSEcCtD
Sirolimus—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000309	0.000739	CcSEcCtD
Sirolimus—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000309	0.000739	CcSEcCtD
Sirolimus—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000309	0.000739	CcSEcCtD
Sirolimus—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.000737	CcSEcCtD
Sirolimus—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000307	0.000735	CcSEcCtD
Sirolimus—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000307	0.000734	CcSEcCtD
Sirolimus—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000307	0.000734	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000306	0.000731	CcSEcCtD
Sirolimus—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000303	0.000725	CcSEcCtD
Sirolimus—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000303	0.000725	CcSEcCtD
Sirolimus—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.0003	0.000719	CcSEcCtD
Sirolimus—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.0003	0.000718	CcSEcCtD
Sirolimus—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000296	0.000709	CcSEcCtD
Sirolimus—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000296	0.000709	CcSEcCtD
Sirolimus—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000296	0.000709	CcSEcCtD
Sirolimus—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000296	0.000709	CcSEcCtD
Sirolimus—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000296	0.000707	CcSEcCtD
Sirolimus—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000295	0.000707	CcSEcCtD
Sirolimus—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000293	0.000701	CcSEcCtD
Sirolimus—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000293	0.0007	CcSEcCtD
Sirolimus—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000293	0.0007	CcSEcCtD
Sirolimus—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000292	0.000698	CcSEcCtD
Sirolimus—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000291	0.000697	CcSEcCtD
Sirolimus—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00029	0.000695	CcSEcCtD
Sirolimus—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00029	0.000695	CcSEcCtD
Sirolimus—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.00029	0.000694	CcSEcCtD
Sirolimus—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.000693	CcSEcCtD
Sirolimus—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000287	0.000687	CcSEcCtD
Sirolimus—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000286	0.000684	CcSEcCtD
Sirolimus—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000284	0.000681	CcSEcCtD
Sirolimus—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00028	0.00067	CcSEcCtD
Sirolimus—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00028	0.00067	CcSEcCtD
Sirolimus—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.000661	CcSEcCtD
Sirolimus—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000276	0.000661	CcSEcCtD
Sirolimus—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000276	0.00066	CcSEcCtD
Sirolimus—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000275	0.000659	CcSEcCtD
Sirolimus—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000273	0.000654	CcSEcCtD
Sirolimus—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000271	0.000648	CcSEcCtD
Sirolimus—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.000644	CcSEcCtD
Sirolimus—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000269	0.000644	CcSEcCtD
Sirolimus—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000265	0.000635	CcSEcCtD
Sirolimus—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.000635	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000265	0.000634	CcSEcCtD
Sirolimus—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000264	0.000631	CcSEcCtD
Sirolimus—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000261	0.000625	CcSEcCtD
Sirolimus—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.000624	CcSEcCtD
Sirolimus—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00026	0.000622	CcSEcCtD
Sirolimus—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000257	0.000614	CcSEcCtD
Sirolimus—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.000614	CcSEcCtD
Sirolimus—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000254	0.000609	CcSEcCtD
Sirolimus—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.000608	CcSEcCtD
Sirolimus—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000251	0.000601	CcSEcCtD
Sirolimus—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.000599	CcSEcCtD
Sirolimus—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.000593	CcSEcCtD
Sirolimus—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000248	0.000593	CcSEcCtD
Sirolimus—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000243	0.000581	CcSEcCtD
Sirolimus—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000243	0.000581	CcSEcCtD
Sirolimus—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00058	CcSEcCtD
Sirolimus—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000239	0.000572	CcSEcCtD
Sirolimus—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000238	0.000571	CcSEcCtD
Sirolimus—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000238	0.000571	CcSEcCtD
Sirolimus—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000236	0.000566	CcSEcCtD
Sirolimus—Rash—Formoterol—chronic obstructive pulmonary disease	0.000236	0.000566	CcSEcCtD
Sirolimus—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000236	0.000565	CcSEcCtD
Sirolimus—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000236	0.000565	CcSEcCtD
Sirolimus—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000565	CcSEcCtD
Sirolimus—Headache—Formoterol—chronic obstructive pulmonary disease	0.000235	0.000562	CcSEcCtD
Sirolimus—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.000562	CcSEcCtD
Sirolimus—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000235	0.000562	CcSEcCtD
Sirolimus—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00056	CcSEcCtD
Sirolimus—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000234	0.00056	CcSEcCtD
Sirolimus—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000234	0.000559	CcSEcCtD
Sirolimus—Rash—Montelukast—chronic obstructive pulmonary disease	0.000232	0.000554	CcSEcCtD
Sirolimus—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000231	0.000554	CcSEcCtD
Sirolimus—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000231	0.000552	CcSEcCtD
Sirolimus—Headache—Montelukast—chronic obstructive pulmonary disease	0.00023	0.000551	CcSEcCtD
Sirolimus—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.000544	CcSEcCtD
Sirolimus—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000227	0.000543	CcSEcCtD
Sirolimus—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.000539	CcSEcCtD
Sirolimus—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000224	0.000537	CcSEcCtD
Sirolimus—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.000534	CcSEcCtD
Sirolimus—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000223	0.000534	CcSEcCtD
Sirolimus—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.000534	CcSEcCtD
Sirolimus—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000223	0.000533	CcSEcCtD
Sirolimus—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.000533	CcSEcCtD
Sirolimus—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.000531	CcSEcCtD
Sirolimus—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.000523	CcSEcCtD
Sirolimus—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000218	0.000522	CcSEcCtD
Sirolimus—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000215	0.000514	CcSEcCtD
Sirolimus—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.000503	CcSEcCtD
Sirolimus—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000209	0.000501	CcSEcCtD
Sirolimus—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000209	0.0005	CcSEcCtD
Sirolimus—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000208	0.000497	CcSEcCtD
Sirolimus—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000207	0.000495	CcSEcCtD
Sirolimus—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000204	0.000488	CcSEcCtD
Sirolimus—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000203	0.000486	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000203	0.000486	CcSEcCtD
Sirolimus—Shock—Prednisolone—chronic obstructive pulmonary disease	0.0002	0.000478	CcSEcCtD
Sirolimus—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000474	CcSEcCtD
Sirolimus—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000196	0.00047	CcSEcCtD
Sirolimus—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000451	CcSEcCtD
Sirolimus—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000449	CcSEcCtD
Sirolimus—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.00044	CcSEcCtD
Sirolimus—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000182	0.000436	CcSEcCtD
Sirolimus—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000181	0.000433	CcSEcCtD
Sirolimus—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.000416	CcSEcCtD
Sirolimus—Tacrolimus—ALB—chronic obstructive pulmonary disease	0.000169	1	CrCbGaD
Sirolimus—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000401	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000167	0.0004	CcSEcCtD
Sirolimus—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000167	0.0004	CcSEcCtD
Sirolimus—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000398	CcSEcCtD
Sirolimus—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000395	CcSEcCtD
Sirolimus—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000163	0.00039	CcSEcCtD
Sirolimus—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000162	0.000388	CcSEcCtD
Sirolimus—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00038	CcSEcCtD
Sirolimus—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000374	CcSEcCtD
Sirolimus—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000368	CcSEcCtD
Sirolimus—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000368	CcSEcCtD
Sirolimus—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000367	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000366	CcSEcCtD
Sirolimus—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000364	CcSEcCtD
Sirolimus—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00015	0.000358	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000353	CcSEcCtD
Sirolimus—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000353	CcSEcCtD
Sirolimus—Infection—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000351	CcSEcCtD
Sirolimus—Shock—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000347	CcSEcCtD
Sirolimus—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000346	CcSEcCtD
Sirolimus—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000345	CcSEcCtD
Sirolimus—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000343	CcSEcCtD
Sirolimus—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000341	CcSEcCtD
Sirolimus—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000141	0.000337	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000322	CcSEcCtD
Sirolimus—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000134	0.000321	CcSEcCtD
Sirolimus—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000319	CcSEcCtD
Sirolimus—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000317	CcSEcCtD
Sirolimus—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000311	CcSEcCtD
Sirolimus—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000307	CcSEcCtD
Sirolimus—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000306	CcSEcCtD
Sirolimus—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000306	CcSEcCtD
Sirolimus—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.000304	CcSEcCtD
Sirolimus—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000302	CcSEcCtD
Sirolimus—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000291	CcSEcCtD
Sirolimus—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000289	CcSEcCtD
Sirolimus—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000289	CcSEcCtD
Sirolimus—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000279	CcSEcCtD
Sirolimus—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000279	CcSEcCtD
Sirolimus—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000109	0.00026	CcSEcCtD
Sirolimus—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000253	CcSEcCtD
Sirolimus—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000104	0.00025	CcSEcCtD
Sirolimus—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000242	CcSEcCtD
Sirolimus—Dizziness—Prednisone—chronic obstructive pulmonary disease	9.76e-05	0.000234	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	9.69e-05	0.000473	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	9.65e-05	0.000471	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.59e-05	0.000468	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.57e-05	0.000467	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—chronic obstructive pulmonary disease	9.53e-05	0.000465	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	9.53e-05	0.000465	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—chronic obstructive pulmonary disease	9.53e-05	0.000465	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—TGFB1—chronic obstructive pulmonary disease	9.51e-05	0.000464	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TLR2—chronic obstructive pulmonary disease	9.49e-05	0.000463	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CXCL8—chronic obstructive pulmonary disease	9.47e-05	0.000462	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	9.46e-05	0.000462	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—chronic obstructive pulmonary disease	9.44e-05	0.000461	CbGpPWpGaD
Sirolimus—Vomiting—Prednisone—chronic obstructive pulmonary disease	9.38e-05	0.000225	CcSEcCtD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—chronic obstructive pulmonary disease	9.36e-05	0.000457	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	9.32e-05	0.000455	CbGpPWpGaD
Sirolimus—Rash—Prednisone—chronic obstructive pulmonary disease	9.31e-05	0.000223	CcSEcCtD
Sirolimus—Dermatitis—Prednisone—chronic obstructive pulmonary disease	9.3e-05	0.000222	CcSEcCtD
Sirolimus—Headache—Prednisone—chronic obstructive pulmonary disease	9.25e-05	0.000221	CcSEcCtD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.08e-05	0.000444	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KL—chronic obstructive pulmonary disease	8.92e-05	0.000435	CbGpPWpGaD
Sirolimus—FGF2—Disease—HDAC2—chronic obstructive pulmonary disease	8.86e-05	0.000432	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—chronic obstructive pulmonary disease	8.82e-05	0.000431	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.8e-05	0.00043	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD8A—chronic obstructive pulmonary disease	8.8e-05	0.000429	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	8.78e-05	0.000429	CbGpPWpGaD
Sirolimus—Nausea—Prednisone—chronic obstructive pulmonary disease	8.77e-05	0.00021	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	8.75e-05	0.000427	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	8.74e-05	0.000427	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	8.69e-05	0.000424	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.55e-05	0.000418	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	8.52e-05	0.000416	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	8.48e-05	0.000414	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.44e-05	0.000412	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	8.44e-05	0.000412	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	8.4e-05	0.00041	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	8.4e-05	0.00041	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.33e-05	0.000407	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	8.27e-05	0.000404	CbGpPWpGaD
Sirolimus—FGF2—Disease—KL—chronic obstructive pulmonary disease	8.23e-05	0.000402	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	8.22e-05	0.000401	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.18e-05	0.0004	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB3—chronic obstructive pulmonary disease	8.18e-05	0.000399	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB3—chronic obstructive pulmonary disease	8.14e-05	0.000398	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	8.01e-05	0.000391	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	7.98e-05	0.000389	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	7.9e-05	0.000386	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	7.86e-05	0.000384	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	7.82e-05	0.000382	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	7.81e-05	0.000381	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CRP—chronic obstructive pulmonary disease	7.79e-05	0.00038	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—IL6—chronic obstructive pulmonary disease	7.78e-05	0.00038	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.78e-05	0.00038	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—VEGFA—chronic obstructive pulmonary disease	7.69e-05	0.000375	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.64e-05	0.000373	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.61e-05	0.000372	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.48e-05	0.000365	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—TLR4—chronic obstructive pulmonary disease	7.47e-05	0.000365	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	7.45e-05	0.000364	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	7.32e-05	0.000358	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	7.32e-05	0.000358	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—chronic obstructive pulmonary disease	7.32e-05	0.000358	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	7.26e-05	0.000354	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	7.19e-05	0.000351	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD8A—chronic obstructive pulmonary disease	7.19e-05	0.000351	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	7.16e-05	0.00035	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.04e-05	0.000344	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TLR2—chronic obstructive pulmonary disease	7.04e-05	0.000344	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.03e-05	0.000343	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.02e-05	0.000343	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—MMP9—chronic obstructive pulmonary disease	6.99e-05	0.000341	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.96e-05	0.00034	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.94e-05	0.000339	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL1B—chronic obstructive pulmonary disease	6.86e-05	0.000335	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	6.84e-05	0.000334	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NOS2—chronic obstructive pulmonary disease	6.79e-05	0.000332	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—IL6—chronic obstructive pulmonary disease	6.72e-05	0.000328	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB3—chronic obstructive pulmonary disease	6.69e-05	0.000326	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KL—chronic obstructive pulmonary disease	6.62e-05	0.000323	CbGpPWpGaD
Sirolimus—MTOR—Disease—HDAC2—chronic obstructive pulmonary disease	6.57e-05	0.000321	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	6.49e-05	0.000317	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	6.49e-05	0.000317	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.47e-05	0.000316	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.38e-05	0.000312	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.36e-05	0.00031	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.3e-05	0.000307	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	6.28e-05	0.000306	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.28e-05	0.000306	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	6.2e-05	0.000303	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB3—chronic obstructive pulmonary disease	6.17e-05	0.000301	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.13e-05	0.0003	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CRP—chronic obstructive pulmonary disease	6.11e-05	0.000298	CbGpPWpGaD
Sirolimus—MTOR—Disease—KL—chronic obstructive pulmonary disease	6.11e-05	0.000298	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.05e-05	0.000295	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TLR4—chronic obstructive pulmonary disease	5.86e-05	0.000286	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—chronic obstructive pulmonary disease	5.81e-05	0.000284	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KL—chronic obstructive pulmonary disease	5.77e-05	0.000282	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	5.76e-05	0.000281	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SERPINE1—chronic obstructive pulmonary disease	5.72e-05	0.000279	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.7e-05	0.000278	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—chronic obstructive pulmonary disease	5.65e-05	0.000276	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.63e-05	0.000275	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GCLC—chronic obstructive pulmonary disease	5.57e-05	0.000272	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.49e-05	0.000268	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NOS3—chronic obstructive pulmonary disease	5.46e-05	0.000267	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.46e-05	0.000267	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—chronic obstructive pulmonary disease	5.38e-05	0.000263	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD8A—chronic obstructive pulmonary disease	5.34e-05	0.00026	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	5.32e-05	0.00026	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—chronic obstructive pulmonary disease	5.32e-05	0.00026	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.31e-05	0.000259	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—chronic obstructive pulmonary disease	5.23e-05	0.000255	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.21e-05	0.000255	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.19e-05	0.000253	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.17e-05	0.000252	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	5.16e-05	0.000252	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOS2—chronic obstructive pulmonary disease	5.15e-05	0.000251	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	5.11e-05	0.000249	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.1e-05	0.000249	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CTGF—chronic obstructive pulmonary disease	5.08e-05	0.000248	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—chronic obstructive pulmonary disease	4.99e-05	0.000244	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—chronic obstructive pulmonary disease	4.99e-05	0.000244	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB3—chronic obstructive pulmonary disease	4.96e-05	0.000242	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.94e-05	0.000241	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	4.93e-05	0.000241	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.8e-05	0.000234	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	4.79e-05	0.000234	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.76e-05	0.000232	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.68e-05	0.000229	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	4.66e-05	0.000228	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.62e-05	0.000226	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.6e-05	0.000225	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB3—chronic obstructive pulmonary disease	4.58e-05	0.000224	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CRP—chronic obstructive pulmonary disease	4.54e-05	0.000221	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TLR4—chronic obstructive pulmonary disease	4.35e-05	0.000212	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—chronic obstructive pulmonary disease	4.34e-05	0.000212	CbGpPWpGaD
Sirolimus—FGF2—Disease—SERPINE1—chronic obstructive pulmonary disease	4.33e-05	0.000212	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.32e-05	0.000211	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.3e-05	0.00021	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	4.29e-05	0.000209	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.28e-05	0.000209	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.18e-05	0.000204	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.16e-05	0.000203	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOS3—chronic obstructive pulmonary disease	4.14e-05	0.000202	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.12e-05	0.000201	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—chronic obstructive pulmonary disease	4.02e-05	0.000196	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4e-05	0.000196	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.95e-05	0.000193	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	3.94e-05	0.000192	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.9e-05	0.000191	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.87e-05	0.000189	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	3.86e-05	0.000188	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.85e-05	0.000188	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.83e-05	0.000187	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.82e-05	0.000187	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS2—chronic obstructive pulmonary disease	3.82e-05	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1B—chronic obstructive pulmonary disease	3.81e-05	0.000186	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.76e-05	0.000183	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.74e-05	0.000182	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—chronic obstructive pulmonary disease	3.7e-05	0.000181	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	3.69e-05	0.00018	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	3.68e-05	0.000179	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—chronic obstructive pulmonary disease	3.61e-05	0.000176	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.59e-05	0.000175	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.58e-05	0.000175	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	3.56e-05	0.000174	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—chronic obstructive pulmonary disease	3.54e-05	0.000173	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.53e-05	0.000173	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.53e-05	0.000172	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.45e-05	0.000168	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.4e-05	0.000166	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.39e-05	0.000166	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.38e-05	0.000165	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	3.37e-05	0.000165	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.29e-05	0.000161	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.27e-05	0.00016	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.24e-05	0.000158	CbGpPWpGaD
Sirolimus—MTOR—Disease—SERPINE1—chronic obstructive pulmonary disease	3.22e-05	0.000157	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.21e-05	0.000157	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	3.18e-05	0.000155	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.12e-05	0.000152	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.11e-05	0.000152	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.09e-05	0.000151	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS3—chronic obstructive pulmonary disease	3.07e-05	0.00015	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.07e-05	0.00015	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.03e-05	0.000148	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.96e-05	0.000144	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—chronic obstructive pulmonary disease	2.91e-05	0.000142	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.9e-05	0.000141	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.87e-05	0.00014	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.85e-05	0.000139	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.84e-05	0.000139	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—chronic obstructive pulmonary disease	2.83e-05	0.000138	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.82e-05	0.000138	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	2.79e-05	0.000136	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.75e-05	0.000134	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—chronic obstructive pulmonary disease	2.74e-05	0.000134	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—chronic obstructive pulmonary disease	2.72e-05	0.000133	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—chronic obstructive pulmonary disease	2.68e-05	0.000131	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.6e-05	0.000127	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.59e-05	0.000126	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.57e-05	0.000125	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.55e-05	0.000125	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.54e-05	0.000124	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.53e-05	0.000123	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.48e-05	0.000121	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.47e-05	0.000121	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.38e-05	0.000116	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.34e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.32e-05	0.000114	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—chronic obstructive pulmonary disease	2.31e-05	0.000113	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.26e-05	0.00011	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.25e-05	0.00011	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—chronic obstructive pulmonary disease	2.23e-05	0.000109	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.21e-05	0.000108	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—chronic obstructive pulmonary disease	2.16e-05	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.15e-05	0.000105	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	2.12e-05	0.000104	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.09e-05	0.000102	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.08e-05	0.000102	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—chronic obstructive pulmonary disease	2.06e-05	0.000101	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—chronic obstructive pulmonary disease	2.03e-05	9.91e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	2.03e-05	9.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—chronic obstructive pulmonary disease	1.99e-05	9.72e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.95e-05	9.54e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.93e-05	9.41e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.92e-05	9.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.91e-05	9.31e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.91e-05	9.3e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.88e-05	9.17e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.8e-05	8.77e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.74e-05	8.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.73e-05	8.42e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.72e-05	8.38e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.7e-05	8.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—chronic obstructive pulmonary disease	1.66e-05	8.09e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.58e-05	7.7e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.57e-05	7.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.55e-05	7.56e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	1.53e-05	7.49e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—chronic obstructive pulmonary disease	1.53e-05	7.47e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	1.47e-05	7.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.44e-05	7.05e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.44e-05	7.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.42e-05	6.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.39e-05	6.81e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.2e-05	5.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.19e-05	5.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.17e-05	5.72e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.16e-05	5.65e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.11e-05	5.41e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.11e-05	5.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.07e-05	5.23e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.05e-05	5.12e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	7.13e-06	3.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	6.82e-06	3.33e-05	CbGpPWpGaD
